-
EP3765448
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3765448
| EP3765448 - NEW POLYMORPHS AND NEW PATH TO SYNTHESIZE TAFAMIDIS [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 01.07.2022 Database last updated on 29.10.2024 | |
| Former | Examination is in progress Status updated on 28.10.2021 | ||
| Former | Request for examination was made Status updated on 18.12.2020 | ||
| Former | The international publication has been made Status updated on 21.09.2019 | ||
| Former | unknown Status updated on 02.04.2019 | Most recent event Tooltip | 01.07.2022 | Application deemed to be withdrawn | published on 03.08.2022 [2022/31] | Applicant(s) | For all designated states AZAD Pharma AG Durachweg 15 8200 Schaffhausen / CH | [2021/03] | Inventor(s) | 01 /
BARSEGHYAN, Karine 89 Andanik str. 31 apt. Yerevan, 0004 / AM | 02 /
HAMBARDZUMYAN, Davit Duryan Street 49/54 Avan Yerevan, 0044 / AM | 03 /
GEVORGYAN, Grigor apt.33, building 7 Barekamutyan str Abovyan city, 2207 / AM | 04 /
KARAPETYAN, Dr. Vahuni Dzorapi Street 38 Dzoraghbyur Kotayk Marz, 2224 / AM | 05 /
NERKARARYAN, Kristine vil. Gandzaqar str. 27 h.7 Tavush, 4007 / AM | 06 /
MAIER, Thomas Panoramaweg 31 78333 Stockach / DE | [2021/03] | Representative(s) | Michalski Hüttermann & Partner Patentanwälte mbB Kaistraße 16A 40221 Düsseldorf / DE | [N/P] |
| Former [2021/03] | Michalski Hüttermann & Partner Patentanwälte mbB Speditionstraße 21 40221 Düsseldorf / DE | Application number, filing date | 19712155.1 | 13.03.2019 | [2021/03] | WO2019EP56317 | Priority number, date | GB20180004005 | 13.03.2018 Original published format: GB 201804005 | [2021/03] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2019175263 | Date: | 19.09.2019 | Language: | EN | [2019/38] | Type: | A1 Application with search report | No.: | EP3765448 | Date: | 20.01.2021 | Language: | EN | The application published by WIPO in one of the EPO official languages on 19.09.2019 takes the place of the publication of the European patent application. | [2021/03] | Search report(s) | International search report - published on: | EP | 19.09.2019 | Classification | IPC: | C07D263/57, A61P25/00, A61K31/423 | [2021/03] | CPC: |
C07D263/57 (EP,GB,US);
A61K31/423 (GB);
A61P25/00 (EP,GB);
C07B2200/13 (EP,US)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2021/03] | Title | German: | NEUE POLYMORPHE UND NEUE WEGE ZUR SYNTHESE VON TAFAMIDIS | [2021/03] | English: | NEW POLYMORPHS AND NEW PATH TO SYNTHESIZE TAFAMIDIS | [2021/03] | French: | NOUVEAUX POLYMORPHES ET NOUVELLE VOIE DE SYNTHÈSE DE TAFAMIDIS | [2021/03] | Entry into regional phase | 09.10.2020 | National basic fee paid | 09.10.2020 | Designation fee(s) paid | 09.10.2020 | Examination fee paid | Examination procedure | 09.10.2020 | Examination requested [2021/03] | 09.10.2020 | Date on which the examining division has become responsible | 27.04.2021 | Amendment by applicant (claims and/or description) | 27.10.2021 | Despatch of a communication from the examining division (Time limit: M04) | 08.03.2022 | Application deemed to be withdrawn, date of legal effect [2022/31] | 29.03.2022 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time [2022/31] | Fees paid | Renewal fee | 30.03.2021 | Renewal fee patent year 03 | Penalty fee | Additional fee for renewal fee | 31.03.2022 | 04 M06 Not yet paid |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [IDA]WO2016038500 (PFIZER [US]) [ID] 11 * Abstract; page 13, line 23 to page 14, line 2; pages 27-29: examples; pages 10-11: description of drawings; figures 1, 2: PXRD data of form 1; figures 3, 4: PXRD data of form 4; figure 13: PXRD pattern of form 2; figures 14, 15: PXRD data of form 6. * [A] 1-10,12,13; | [AD]WO2013038351 (PFIZER [US], et al) [AD] 1-13 * Abstract; page 1, paragraphs 1, 2; page 16, last paragraph to page 17, paragraph 2; page 19, lines 7-14; page 27, example 1; claims 1-4, 10, 12-13; figures 1A and 1B. *; | [A] - Griesser, "Chapter 8. The Importance of Solvates", Polymorphism in the Pharmaceutical Industry, WEINHEIM (DE), WILEY-VCH, (2006), pages 211 - 215, ISBN 978-3-527-31146-0, XP055582446 [A] 1-10,12,13 * Page 211, paragraph 1. * | [L] - Bernstein, "Chapter 1.2.1 Polymorphism", POLYMORPHISM IN MOLECULAR CRYSTALS, OXFORD, GB, CLARENDON PRESS, (2002), pages 2 - 4, ISBN 978-0-19-850605-8, XP055582436 [L] 1,4,5,7 * Page 2, penultimate paragraph; page 4, paragraph 3, last sentence. Cited as common general knowledge. * | [L] - CAIRA, "Crystalline Polymorphism of Organic Compounds", TOPICS IN CURRENT CHEMISTRY, (1998), vol. 198, ISSN 0340-1022, pages 163 - 208, XP008166276 [L] 11 * Paragraph bridging pages 165 and 166. Cited as common general knowledge. * DOI: http://dx.doi.org/10.1007/3-540-69178-2_5 | [L] - BYRN ET AL., "Pharmaceutical Solids: A Strategic Approach to Regulatory Considerations", PHARMACEUTICAL RESEARCH, (19950101), vol. 12, no. 7, doi:10.1023/A:1016241927429, pages 945 - 954, XP055531015 [L] 11 * Abstract; page 946, right column, paragraphs 2, 3. Cited as common general knowledge. * DOI: http://dx.doi.org/10.1023/A:1016241927429 |